Study to Investigate Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years and Over With Moderate to Severe Atopic Dermatitis With the Option of Rescue Treatment in Flaring Subjects
Status: | Recruiting |
---|---|
Conditions: | Skin Cancer, Psoriasis, Skin and Soft Tissue Infections, Infectious Disease, Neurology, Women's Studies, Dermatology, Dermatology, Dermatology |
Therapuetic Areas: | Dermatology / Plastic Surgery, Immunology / Infectious Diseases, Neurology, Oncology, Reproductive |
Healthy: | No |
Age Range: | 12 - Any |
Updated: | 3/27/2019 |
Start Date: | June 11, 2018 |
End Date: | July 3, 2020 |
Contact: | Pfizer CT.gov Call Center |
Email: | ClinicalTrials.gov_Inquiries@pfizer.com |
Phone: | 1-800-718-1021 |
A PHASE 3 RANDOMIZED WITHDRAWAL, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTI-CENTER STUDY INVESTIGATING THE EFFICACY AND SAFETY OF PF-04965842 IN SUBJECTS AGED 12 YEARS AND OVER, WITH MODERATE TO SEVERE ATOPIC DERMATITIS WITH THE OPTION OF RESCUE TREATMENT IN FLARING SUBJECTS
B7451014 is a Phase 3 study to investigate PF-04965842 in patients aged 12 years and over
with a minimum body weight of 40 kg who have moderate to severe atopic dermatitis. Subjects
responding well to an initial open-label 12 week treatment of PF-04965842 (200 mg) taken
orally once daily (QD) will be identified and randomized in a double-blind manner to receive
200 mg QD PF-04965842, 100 mg QD PF-04965842, or QD placebo. Efficacy and safety of 2 doses
of PF-04965842 will be evaluated relative to placebo over 40 weeks. Subjects experiencing
significant worsening of their symptoms, i.e., protocol-defined flare, enter 12 weeks rescue
treatment and receive 200 mg PF-04965842 together with a marketed topical medicine. Eligible
patients will have the option to enter a long-term extension study after completing the
initial 12 week treatment, the 12 week rescue treatment, and the 40 week blinded treatment.
with a minimum body weight of 40 kg who have moderate to severe atopic dermatitis. Subjects
responding well to an initial open-label 12 week treatment of PF-04965842 (200 mg) taken
orally once daily (QD) will be identified and randomized in a double-blind manner to receive
200 mg QD PF-04965842, 100 mg QD PF-04965842, or QD placebo. Efficacy and safety of 2 doses
of PF-04965842 will be evaluated relative to placebo over 40 weeks. Subjects experiencing
significant worsening of their symptoms, i.e., protocol-defined flare, enter 12 weeks rescue
treatment and receive 200 mg PF-04965842 together with a marketed topical medicine. Eligible
patients will have the option to enter a long-term extension study after completing the
initial 12 week treatment, the 12 week rescue treatment, and the 40 week blinded treatment.
Responder criteria for randomization at week 12 are defined as a) achieving an IGA of clear
(0) or almost clear (1) (on a 5 point scale), b) a reduction from IGA baseline of 2 or more
points, and c) reaching an EASI-75 response compared to baseline. Flare requiring rescue
treatment is defined as a loss of at least 50% of the EASI response at Week 12 and an IGA
score of 2 or higher.
(0) or almost clear (1) (on a 5 point scale), b) a reduction from IGA baseline of 2 or more
points, and c) reaching an EASI-75 response compared to baseline. Flare requiring rescue
treatment is defined as a loss of at least 50% of the EASI response at Week 12 and an IGA
score of 2 or higher.
Inclusion Criteria:
- 12 years of age or older with a minimum body weight of 40 kg
- Diagnosis of atopic dermatitis (AD) for at least 1 year and current status of moderate
to severe disease (>= the following scores: BSA10%, IGA 3, EASI 16, Pruritus NRS 4)
- Recent history of inadequate response or inability to tolerate topical AD treatments
or require systemic treatments for AD control
Exclusion Criteria:
- Unwilling to discontinue current AD medications prior to the study or require
treatment with prohibited medications during the study
- Prior treatment with JAK inhibitors
- Other active nonAD inflammatory skin diseases or conditions affecting skin
- Medical history including thrombocytopenia, coagulopathy or platelet dysfunction, Q
wave interval abnormalities, current or history of certain infections, cancer,
lymphoproliferative disorders and other medical conditions at the discretion of the
investigator
- Pregnant or breastfeeding women, or women of childbearing potential who are unwilling
to use contraception
We found this trial at
60
sites
Boston Children's Hospital Boston Children's Hospital is a 395-bed comprehensive center for pediatric health care....
Click here to add this to my saved trials
Emory University Emory University, recognized internationally for its outstanding liberal artscolleges, graduate and professional schools,...
Click here to add this to my saved trials
Tufts Medical Center Tufts Medical Center is an internationally-respected academic medical center – a teaching...
Click here to add this to my saved trials
Childrens Hospital Los Angeles Children's Hospital Los Angeles is a 501(c)(3) nonprofit hospital for pediatric...
Click here to add this to my saved trials
Univ of Rochester Medical Center One of the nation's top academic medical centers, the University...
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
500 22nd Street South
Birmingham, Alabama 35233
Birmingham, Alabama 35233
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
17271 Brookhurst Street
Fountain Valley, California 92708
Fountain Valley, California 92708
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
1430 Tulane Ave Suite SL32
New Orleans, Louisiana 70112
New Orleans, Louisiana 70112
(504) 588-5912
Tulane University Health Sciences Center One of the nation's most recognized centers for medical education,...
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Lynn Health Science Institute Our mission is to provide clinical trials research and health services...
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
9933 Woods Drive
Skokie, Illinois 60077
Skokie, Illinois 60077
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials